Alkem Laboratories Ltd (ALKEM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Alkem Laboratories Ltd (ALKEM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9778
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alkem Laboratories Ltd (Alkem) is a pharmaceutical company that develops, manufactures and markets generic and specialty pharmaceutical products. The company’s products include active pharmaceutical ingredients, generic products, branded products and nutraceuticals. Alkem provides drugs for acute and chronic diseases such as central nervous system disorders, gastro-intestinal infections, diabetes, malaria, pain, cardiovascular diseases and immune disorders. It offers vitamins, minerals and nutrition products. The company distributes its products through a wide network of distributors all over India. It exports products to Europe, Australia, South-East Asia, North America, South America, Russia-CIS and Africa. Alkem is headquartered in Mumbai, Maharashtra, India.

Alkem Laboratories Ltd (ALKEM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Alkem Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Alkem Labs Acquires Formulation Manufacturing Facility from Long Pharma 13
Alkem Labs Acquires Manufacturing Assets from NORAC 14
Partnerships 15
Alkem Labs Enters into Agreement with Haw Par 15
Licensing Agreements 16
Alkem Labs Enters into Licensing Agreement with Stempeutics Research 16
Alkem Enters into Licensing Agreement with MediPost for Cartistem 17
Dong-A Pharma Enters Into Licensing Agreement With Alkem Labs For DA-1229 18
Equity Offering 19
Alkem Labs Raises USD202 Million in IPO 19
Asset Transactions 21
Ordain Health Care Acquires Fertica Business from Alkem Labs for USD4 Million 21
Acquisition 22
Alkem Labs Acquires 51% Stake in Cachet Pharma 22
Alkem Labs Acquires 51% Stake in Indchemie Health Specialities 23
Alkem Labs Acquires Remaining 20% Stake in Enzene Biosciences 24
Alkem Labs Acquires Remaining 80% Stake in Pharmacor from S&B 25
Alkem Laboratories Ltd – Key Competitors 26
Alkem Laboratories Ltd – Key Employees 27
Alkem Laboratories Ltd – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 30
Financial Announcements 30
May 30, 2018: Alkem reports Q4FY18 and FY18 Results 30
Aug 11, 2017: Alkem Reports Q1FY18 Results 32
Corporate Communications 33
Oct 31, 2017: Alkem Laboratories: Resignation of Chief Executive Officer (CEO) 33
May 17, 2017: Alkem Laboratories Announces resignation of Independent Director 34
Legal and Regulatory 35
Aug 11, 2018: Alkem Laboratories provides update on the US FDA Inspection at Manufacturing Facility at California, USA 35
Aug 10, 2018: Update on US FDA inspection at Alkem’s Baddi Facility 36
Jul 24, 2018: Alkem receives EIR from the US FDA for its Daman formulation facility 37
Mar 28, 2018: Alkem Labs: Update on USFDA Inspection at its manufacturing facility at Amaliya in India 38
Jan 10, 2018: Update on US FDA Inspection at Alkem’s Baddi Facility 39
Jan 10, 2018: Alkem receives EIR from the US FDA for its Baddi formulation facility 40
Oct 28, 2017: US FDA completes inspection at Alkem Laboratories’s St Louis facility 41
Sep 18, 2017: Alkem Announces Update on US FDA Inspection at Alkem’s Baddi Facility 42
Jul 14, 2017: Update on US FDA inspection for Bioequivalence Facility at Taloja 43
May 23, 2017: Alkem receives EIR from the US FDA for its Baddi Management Manufacturing Facility 44
Mar 29, 2017: Alkem receives EIR from the US FDA for its Alkem’s Ankaleshwar API Facility 45
Mar 10, 2017: Alkem Laboratories Announces Update on US FDA Inspection at Alkem s Baddi Facility 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alkem Laboratories Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Alkem Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Alkem Labs Acquires Formulation Manufacturing Facility from Long Pharma 13
Alkem Labs Acquires Manufacturing Assets from NORAC 14
Alkem Labs Enters into Agreement with Haw Par 15
Alkem Labs Enters into Licensing Agreement with Stempeutics Research 16
Alkem Enters into Licensing Agreement with MediPost for Cartistem 17
Dong-A Pharma Enters Into Licensing Agreement With Alkem Labs For DA-1229 18
Alkem Labs Raises USD202 Million in IPO 19
Ordain Health Care Acquires Fertica Business from Alkem Labs for USD4 Million 21
Alkem Labs Acquires 51% Stake in Cachet Pharma 22
Alkem Labs Acquires 51% Stake in Indchemie Health Specialities 23
Alkem Labs Acquires Remaining 20% Stake in Enzene Biosciences 24
Alkem Labs Acquires Remaining 80% Stake in Pharmacor from S&B 25
Alkem Laboratories Ltd, Key Competitors 26
Alkem Laboratories Ltd, Key Employees 27
Alkem Laboratories Ltd, Subsidiaries 28

List of Figures
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Alkem Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Alkem Laboratories Ltd (ALKEM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Health Net Inc:企業の戦略的SWOT分析
    Health Net Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Southern Petrochemical Industries Corp Ltd (SPIC):企業の財務・戦略的SWOT分析
    Summary Southern Petrochemical Industries Corp Ltd (SPIC) is a chemical company that manufactures fertilizers for agriculture. The company offers products such as chemical fertilizer, organic and water soluble fertilizers, plant growth regulators, micro nutrients, and industrial products. Its chemic …
  • British Airways Plc:企業の戦略・SWOT・財務情報
    British Airways Plc - Strategy, SWOT and Corporate Finance Report Summary British Airways Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • miacom diagnostics GmbH:製品パイプライン分析
    Summary miacom diagnostics GmbH (miacom) is a molecular diagnostic company that develops and distributes molecular diagnostic tests. The company offers products such as hemoFISH, which identifies sepsis-related pathogens directly from positive blood culture bottles; respiFISH that identifies pathoge …
  • Neiman Marcus Group LTD LLC:企業の戦略的SWOT分析
    Neiman Marcus Group LTD LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Public Power Corporation SA:発電所・企業SWOT分析
    Public Power Corporation SA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key e …
  • BioDelivery Sciences International Inc (BDSI):企業の財務・戦略的SWOT分析
    BioDelivery Sciences International Inc (BDSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • BEML Ltd:企業の戦略・SWOT・財務情報
    BEML Ltd - Strategy, SWOT and Corporate Finance Report Summary BEML Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Ichor Medical Systems Inc-製薬・医療分野:企業M&A・提携分析
    Summary Ichor Medical Systems Inc (Ichor) is a medical equipment company that commercializes electroporation technology for the delivery of vaccines and DNA drugs. The company electroporation technology is used for the treatment and prevention of debilitating diseases. Its trigrid provides DNA drugs …
  • Eurofins MWG Operon LLC-製薬・医療分野:企業M&A・提携分析
    Summary Eurofins MWG Operon LLC (Eurofins) is a biotechnology company that provides DNA sequencing, DNA synthesis and bioinformatic services. The company’s products include DNA tube oligos, large scale synthesis, large scale synthesis, oligo modifications, oligo modifications, real-time QPCR probes, …
  • Suedzucker Ag:企業の戦略・SWOT・財務分析
    Suedzucker Ag - Strategy, SWOT and Corporate Finance Report Summary Suedzucker Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Strata-X Energy Ltd (SXE):石油・ガス:M&Aディール及び事業提携情報
    Summary Strata-X Energy Ltd (Strata-X Energy), formerly Strata-X Ltd, is an independent oil and gas exploration company. The company operates in the acquisition, exploration and development of oil and gas properties in the US states of California and Illinois and in the Republic of Botswana. It prov …
  • BBX Capital Corporation:企業の戦略・SWOT・財務情報
    BBX Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary BBX Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Federal Grid Company of Unified Energy System (FEES):電力:M&Aディール及び事業提携情報
    Summary Federal Grid Company of Unified Energy System (FGC UES), a subsidiary of Rosseti, is an energy company. It operates and manages unified national electricity transmission grid system. The company transmits electricity to distribution grid companies, large commercial end customers and retail e …
  • Strongbridge Biopharma plc (SBBP)-製薬・医療分野:企業M&A・提携分析
    Summary Strongbridge Biopharma plc (Strongbridge), formerly Cortendo plc, is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokale …
  • KAHR medical Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary KAHR medical Ltd (KAHR), a subsidiary of Hadasit Bio-Holdings Ltd, is a drug manufacturing company that develops fusion protein pharmaceuticals. The company's drug development pipeline is built around Dual Signaling Proteins (DSP) technology. Its pipeline products comprise DSP105, DSP106 and …
  • Capstone Turbine Corp (CPST):電力:M&Aディール及び事業提携情報
    Summary Capstone Turbine Corp (CPST) is an energy company. It develops, manufactures, markets, and services microturbine technology solutions and power generation systems. The company integrates air bearing technology, advanced combustion technology, and power electronics to form efficient and ultra …
  • Transplant Genomics Inc:企業の製品パイプライン分析2018
    Summary Transplant Genomics Inc (TGI) is a biotech company. The company carries out performing organ transplantation using non-invasive serial monitoring under the guidance of genomics. It aims in detecting early signs of graft injury by conducting molecular diagnostic tests, enabling in differentia …
  • BUCA, Inc.:企業の戦略・SWOT・財務情報
    BUCA, Inc. - Strategy, SWOT and Corporate Finance Report Summary BUCA, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Nationwide Building Society:企業のM&A・事業提携・投資動向
    Nationwide Building Society - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Nationwide Building Society Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆